{"protocolSection":{"identificationModule":{"nctId":"NCT03875092","orgStudyIdInfo":{"id":"3475-407 China Extension"},"secondaryIdInfos":[{"id":"173568","type":"REGISTRY","domain":"JAPIC-CTI"},{"id":"MK-3475-407","type":"OTHER","domain":"MSD Protocol Number"},{"id":"KEYNOTE-407","type":"OTHER","domain":"MSD"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study","officialTitle":"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2023-09-14","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-13","studyFirstSubmitQcDate":"2019-03-13","studyFirstPostDateStruct":{"date":"2019-03-14","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-09-21","resultsFirstSubmitQcDate":"2021-10-18","resultsFirstPostDateStruct":{"date":"2021-10-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-09-04","lastUpdatePostDateStruct":{"date":"2024-10-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).\n\nThe primary hypotheses are that treatment with pembrolizumab prolongs: 1) Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor compared to placebo, and 2) Overall Survival (OS) in Chinese participants.\n\nAfter analysis of interim results was conducted, the protocol was amended (Amendment 5) to allow participants the option to discontinue placebo in the control arm and to switch to pembrolizumab in the event of documented progressive disease as assessed by central review.","detailedDescription":"The MK-3475-407-China Extension Study enrolled a total of 125 participants, of which 15 participants have been also previously enrolled in the MK-3475-407 global study (NCT02775435). This China extension study did not include nano particle albumin-bound paclitaxel (nab-paclitaxel) that was an option in the global base study, because nab-paclitaxel it is not yet approved for treatment of NSCLC in China."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":125,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pembrolizumab + Chemotherapy","type":"EXPERIMENTAL","description":"Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.","interventionNames":["Biological: Pembrolizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin","Drug: Saline placebo for pembrolizumab"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"IV infusion","armGroupLabels":["Pembrolizumab + Chemotherapy"],"otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Paclitaxel","description":"IV infusion","armGroupLabels":["Chemotherapy","Pembrolizumab + Chemotherapy"],"otherNames":["TAXOL®"]},{"type":"DRUG","name":"Carboplatin","description":"IV infusion Carboplatin dose should not exceed 900 mg.","armGroupLabels":["Chemotherapy","Pembrolizumab + Chemotherapy"],"otherNames":["PARAPLATIN®"]},{"type":"DRUG","name":"Saline placebo for pembrolizumab","description":"IV infusion","armGroupLabels":["Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","timeFrame":"Up to approximately 33 months"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death due to any cause. OS is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","timeFrame":"Up to approximately 39 months"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1. ORR as assessed by blinded independent central review per RECIST 1.1 is presented.","timeFrame":"Up to approximately 33 months"},{"measure":"Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated a confirmed response (Complete Response \\[CR\\]: Disappearance of all target lesions or Partial Response \\[PR\\]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression as assessed by RECIST 1.1 or death. DOR as assessed by blinded independent central review per RECIST 1.1 is presented.","timeFrame":"Up to approximately 30 months"},{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","timeFrame":"Up to approximately 31 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"The number of participants who discontinued study treatment due to an AE is presented.","timeFrame":"Up to approximately 29 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer \\[AJCC\\]) squamous NSCLC.\n* Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.\n* Has not received prior systemic treatment for metastatic NSCLC.\n* Has provided tumor tissue from locations not radiated prior to biopsy.\n* Has a life expectancy of at least 3 months.\n* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.\n* Has adequate organ function.\n* If female of childbearing potential, is willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of study treatment.\n* If male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study treatment through 95 days after the last dose of study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.\n\nExclusion Criteria:\n\n* Has non-squamous histology NSCLC.\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.\n* Before the first dose of study drug: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease; b) Has received other targeted or biological antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic disease; c) Has had major surgery (\\<3 weeks prior to first dose).\n* Received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study treatment.\n* Completed palliative radiotherapy within 7 days of the first dose of study treatment.\n* Is expected to require any other form of antineoplastic therapy while on study.\n* Has received a live-virus vaccination within 30 days of planned treatment start.\n* Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Has pre-existing peripheral neuropathy that is ≥ Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) Version 4 criteria.\n* Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.\n* Has a known sensitivity to any component of carboplatin or paclitaxel or nab-paclitaxel.\n* Has active autoimmune disease that has required systemic treatment in past 2 years.\n* Is on chronic systemic steroids.\n* Had prior treatment with any other anti-programmed cell death 1 (anti-PD-1), or programmed cell death ligand 1 (PD-L1) or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms.\n* Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.\n* Has an active infection requiring therapy.\n* Has known history of Human Immunodeficiency Virus (HIV).\n* Has known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection.\n* Is, at the time of providing documented informed consent, a regular user (including \"recreational use\") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol).\n* Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Zhongshan Hospital Fudan University","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"references":[{"pmid":"34661177","type":"RESULT","citation":"Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Li B, Hu X, Schwarzenberger P, Paz-Ares L. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep. 2021 Sep 25;2(10):100225. doi: 10.1016/j.jtocrr.2021.100225. eCollection 2021 Oct."},{"pmid":"37465924","type":"DERIVED","citation":"Cheng Y, Yang JC, Okamoto I, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Yan Y, Xiao S, Lin J, Pietanza MC, Kurata T. Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia. Immunotherapy. 2023 Sep;15(13):1029-1044. doi: 10.2217/imt-2023-0043. Epub 2023 Jul 19."}],"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The China extension study included participants previously enrolled in China in the global study for MK-3475-407 (NCT02775435) plus those enrolled during the China extension enrollment period.","groups":[{"id":"FG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"FG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"Switched to Pembrolizumab+Chemotherapy","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"38"}]},{"type":"Received Second Course of Pembrolizumab","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"60"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"51"}]},{"type":"Participation Was Terminated By Sponsor","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"BG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"125"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.6","spread":"8.7"},{"groupId":"BG001","value":"61.5","spread":"9.1"},{"groupId":"BG002","value":"61.5","spread":"8.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"119"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"125"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"125"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS)","description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS \\<1% were classified as not PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"TPS <1%","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"48"}]},{"title":"TPS ≥1%","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"72"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Taxane Chemotherapy","description":"Participants were classified according to their taxane chemotherapy regimen: paclitaxel or nab-paclitaxel.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"+Paclitaxel","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"125"}]},{"title":"+Nab-paclitaxel","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Geographic Region","description":"Participants were classified according to their geographic region: East Asia vs. non-East Asia.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"East Asia","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"125"}]},{"title":"Non-East Asia","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","populationDescription":"The Intent-To-Treat population consisted of all randomized participants, regardless of whether or not they received study treatment. Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 33 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"6.2","upperLimit":"10.5"},{"groupId":"OG001","value":"4.2","lowerLimit":"4.0","upperLimit":"5.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"0.52","estimateComment":"Based on unstratified Cox regression model with treatment as a covariate, due to small sample size."}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death due to any cause. OS is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","populationDescription":"The Intent-To-Treat population consisted of all randomized participants, regardless of whether or not they received study treatment. Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 39 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","lowerLimit":"18.2","upperLimit":"NA","comment":"NA=OS upper limit not reached"},{"groupId":"OG001","value":"12.7","lowerLimit":"9.4","upperLimit":"17.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"0.70","estimateComment":"Based on unstratified Cox regression model with treatment as a covariate, due to small sample size."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1. ORR as assessed by blinded independent central review per RECIST 1.1 is presented.","populationDescription":"The Intent-To-Treat population consisted of all randomized participants, regardless of whether or not they received study treatment. Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to approximately 33 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"68.2","upperLimit":"88.9"},{"groupId":"OG001","value":"43.3","lowerLimit":"30.6","upperLimit":"56.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"36.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"19.9","ciUpperLimit":"51.6","estimateComment":"Based on unstratified Miettinen \\& Nurminen method, due to small sample size."}]},{"type":"SECONDARY","title":"Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated a confirmed response (Complete Response \\[CR\\]: Disappearance of all target lesions or Partial Response \\[PR\\]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression as assessed by RECIST 1.1 or death. DOR as assessed by blinded independent central review per RECIST 1.1 is presented.","populationDescription":"The Intent-To-Treat population consisted of all randomized participants, regardless of whether or not they received study treatment, who demonstrated a confirmed response (CR or PR). Participants were included in the treatment arm to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.9","upperLimit":"14.4"},{"groupId":"OG001","value":"3.5","lowerLimit":"2.8","upperLimit":"4.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.","populationDescription":"The Safety population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 31 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"The number of participants who discontinued study treatment due to an AE is presented.","populationDescription":"The Safety population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 29 months","groups":[{"id":"OG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."},{"id":"OG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-Cause mortality: Up to 1948 days Adverse events: Up to 1625 days","description":"Mortality data were collected for all randomized participants. Adverse event (AE) data were collected for all participants who received ≥1 dose of study treatment. Per protocol, disease progression of cancer under study was not considered an AE unless considered related to study treatment. Therefore Medical Dictionary for Regulatory Activities (MedDRA) terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to study treatment are excluded as AEs.","eventGroups":[{"id":"EG000","title":"Pembrolizumab + Chemotherapy","description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.","deathsNumAffected":41,"deathsNumAtRisk":65,"seriousNumAffected":35,"seriousNumAtRisk":65,"otherNumAffected":65,"otherNumAtRisk":65},{"id":"EG001","title":"Chemotherapy","description":"Participants received normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.","deathsNumAffected":22,"deathsNumAtRisk":60,"seriousNumAffected":22,"seriousNumAtRisk":60,"otherNumAffected":60,"otherNumAtRisk":60},{"id":"EG002","title":"Chemotherapy > Pembrolizumab Switch Over","description":"Eligible participants with documented disease progression following chemotherapy in \"Chemotherapy\" arm switched over to receive pembrolizumab 200 mg IV Q3W for up to 35 administrations (approximately 2 years).","deathsNumAffected":34,"deathsNumAtRisk":38,"seriousNumAffected":10,"seriousNumAtRisk":38,"otherNumAffected":32,"otherNumAtRisk":38},{"id":"EG003","title":"Pembrolizumab > Pembrolizumab Second Course","description":"Eligible participants who received pembrolizumab as a first course (200 mg IV Q3W for up to 35 administrations) and stopped the first course of pembrolizumab due to complete response; or completed the first course of pembrolizumab and had stable disease, partial response, or complete response; but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (approximately 1 year additional).","deathsNumAffected":5,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Gastrointestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":60},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pneumonia fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Acquired tracheo-oesophageal fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Tracheal stenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Peripheral artery aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":103,"numAffected":42,"numAtRisk":65},{"groupId":"EG001","numEvents":85,"numAffected":46,"numAtRisk":60},{"groupId":"EG002","numEvents":17,"numAffected":11,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":12,"numAtRisk":65},{"groupId":"EG001","numEvents":32,"numAffected":7,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":8,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":16,"numAtRisk":65},{"groupId":"EG001","numEvents":21,"numAffected":14,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":11,"numAtRisk":65},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":24,"numAtRisk":65},{"groupId":"EG001","numEvents":22,"numAffected":13,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":15,"numAtRisk":65},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":65},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":65},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":60},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":65},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":60},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":24,"numAtRisk":65},{"groupId":"EG001","numEvents":26,"numAffected":17,"numAtRisk":60},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":19,"numAtRisk":65},{"groupId":"EG001","numEvents":21,"numAffected":13,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":7,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":6}]},{"term":"Blood chloride decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood cholinesterase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":5,"numAffected":2,"numAtRisk":6}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":60},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":38},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":6}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":195,"numAffected":50,"numAtRisk":65},{"groupId":"EG001","numEvents":128,"numAffected":43,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":16,"numAtRisk":65},{"groupId":"EG001","numEvents":37,"numAffected":22,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":6}]},{"term":"Prealbumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":192,"numAffected":51,"numAtRisk":65},{"groupId":"EG001","numEvents":131,"numAffected":42,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":25,"numAtRisk":65},{"groupId":"EG001","numEvents":25,"numAffected":19,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":13,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":7,"numAtRisk":60},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":65},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":16,"numAtRisk":65},{"groupId":"EG001","numEvents":20,"numAffected":12,"numAtRisk":60},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":60},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":23,"numAtRisk":65},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":65},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":29,"numAtRisk":65},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":60},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":11,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Vocal cord disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":51,"numAtRisk":65},{"groupId":"EG001","numEvents":40,"numAffected":40,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":16,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-10-30","uploadDate":"2021-10-18T13:03","filename":"Prot_002.pdf","size":28115294},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-01-29","uploadDate":"2021-10-18T13:03","filename":"SAP_003.pdf","size":7518878}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2021-10-18","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}